Xeris Biopharma Holdings (XERS) Receivables (2020 - 2026)

Xeris Biopharma Holdings' Receivables history runs 7 years deep, the most recent figure standing at $56.3 million for Q1 2026.

• Quarterly Receivables rose 21.51% year-over-year to $56.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.3 million (up 21.51% YoY) and the FY2025 annual result came in at $51.0 million, up 26.31% from the prior year.
• Receivables was $56.3 million for Q1 2026 at Xeris Biopharma Holdings, up from $51.0 million in the prior quarter.
• Across five years, Receivables topped out at $56.3 million in Q1 2026 and bottomed at $23.4 million in Q1 2022.
• A 5-year average of $39.7 million and a median of $40.4 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables surged 102.92% — and 2024, when it retreated 10.5%.
• Xeris Biopharma Holdings' Receivables stood at $30.8 million in 2022, then gained by 27.14% to $39.2 million in 2023, then advanced by 3.11% to $40.4 million in 2024, then advanced by 26.31% to $51.0 million in 2025, then rose by 10.27% to $56.3 million in 2026.
• Business Quant data shows XERS's Receivables at $56.3 million in Q1 2026, $51.0 million in Q4 2025, and $53.8 million in Q3 2025.